NovoMix 30 cuts HbA1c 2.6% in IMPROVE trial

New data from the IMPROVE study show that significant improvements in glycemic control were achieved with Danish insulin giant Novo Nordisk's premixed modern insulin, NovoMix 30, in patients poorly controlled on other, or no previous pharmaceutical treatment. The IMPROVE is the largest ever observational study in diabetes, involving nearly 58,000 patients from 11 countries and was designed to assess the safety and effectiveness of NovoMix 30. The results were announced at the 68th annual meeting of the American Diabetes Association in San Francisco.

The study showed that, on average, patients' overall HbA1c levels dropped significantly - by 2.6% - after treatment with NovoMix 30. While there was a large drop in HbA1c of 2.5 percentage points in patients who had not been previously treated with insulin, an even greater improvement of 3.0 percentage points was seen in those who had been poorly controlled on other insulin regimens. Overall, a total of 71% of patients reached the HbA1c target level of less than or equal to 7% and this was achieved with a 70% reduction in patient-reported major hypoglycemic events and no significant weight gain. Average score of patient satisfaction with treatment rose from 57.2 out of 100 to 74.5 by study end, the firm added.